Distalmotion says it has completed the first US sale and delivery of the Dexter Robotic Surgery System to Memorial Hermann Health System in Houston, Texas in early February. This milestone marks a significant step toward expanding access to robotic-assisted surgery in the United States.
Distalmotion, a MedTech company with more than 1,500 surgical cases completed to date in Europe, is actively expanding within the US with its Dexter robot, which received FDA De Novo market authorization last quarter.
The company’s mission is to increase access to robotics for more surgeons and for outpatient sites of care – where it is limited today by the operational requirements of traditional robots.
One of the largest nonprofit health systems in the nation, Memorial Hermann is an integrated system with more than 6,600 affiliated physicians and more than 34,000 employees. The system serves Southeast Texas and the Greater Houston community with more than 270 care delivery sites, including 17 hospitals.
John Burton, VP, surgical service line at Memorial Hermann Health System, says: “Memorial Hermann is at the forefront of surgical innovation, committed to providing quality, patient-centered care and advancing health.
“We are excited to launch the Dexter robotic surgery program, which will enable access to the benefits of robotic-assisted surgery for more procedures and patients.”
Dexter is designed to provide the benefits of robotics, such as enhanced precision in tight spaces, while uniquely simplifying the operational requirements of a robotics program.
Well-suited to any size operating room (OR) and available for multi-room use, Dexter is easily moved, quickly set up, and seamlessly integrated into site of care protocols and surgical workflows.
Its open architecture also allows healthcare administrators to leverage their existing investments in OR technology to reduce supply chain burden.
The one-of-a-kind sterile surgeon console offers a novel surgeon-patient connection in robotics and provides procedural fluidity in the case a surgeon prefers to perform a specific task themselves at the bedside.
Greg Roche, CEO of Distalmotion, says: “We are delivering on our mission to empower access to the benefits of robotic surgery.
“With their track record of early adoption of innovation, we look forward to kickstarting our US launch with Memorial Hermann and working with them to demonstrate how the latest robotic surgery technology can be effortlessly integrated into hospital and outpatient settings.”
Throughout the rest of this year, Distalmotion will continue to expand in Europe and ramp up commercial activities in the US, including seeking additional indications.
It expects the value Dexter offers to aid more surgeons and sites of care in overcoming operational barriers to traditional robots – especially in outpatient settings – to enable more patients to benefit from robotic surgery.
